Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM et al (1996) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7(2):189–195

PubMed  CAS  Google Scholar 

Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A et al (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754, 030 Antiemetic Trials Group. N Engl J Med 340(3):190–195

Article  PubMed  CAS  Google Scholar 

Almeida EP, Gutierrez MG, Adami NP (2004) [Monitoring and evaluation of side effects of chemotherapy in patients with colon cancer]. Rev Lat Am Enfermagem 12(5):760–766

Article  PubMed  Google Scholar 

Sharma R, Tobin P, Clarke SJ (2005) Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 6(2):93–102

Article  PubMed  CAS  Google Scholar 

Gralla RJ (1991) Controlling emesis in patients receiving cancer chemotherapy. Recent Results Cancer Res 121:68–85

PubMed  CAS  Google Scholar 

Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4(3):191–196

PubMed  CAS  Google Scholar 

Koeller JM, Aapro MS, Gralla RJ, Grunberg SM, Hesketh PJ, Kris MG et al (2002) Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 10(7):519–522

Article  PubMed  Google Scholar 

Aapro MS (2007) Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Clin Risk Manag 3(6):1009–1020

PubMed  Google Scholar 

Navari RM (2006) Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol 2(5):591–602

Article  PubMed  CAS  Google Scholar 

Kris MG, Pisters KM, Hinkley L (1994) Delayed emesis following anticancer chemotherapy. Support Care Cancer 2(5):297–300

Article  PubMed  CAS  Google Scholar 

Herrstedt J (2008) Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 5(1):32–43

Article  PubMed  CAS  Google Scholar 

Navari RM, Province PS (2006) Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs 11(1):137–151

Article  PubMed  CAS  Google Scholar 

Stoltz R, Cyong JC, Shah A, Parisi S (2004) Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 44(5):520–531

Article  PubMed  CAS  Google Scholar 

Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14(10):1570–1577

Article  PubMed  CAS  Google Scholar 

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98(11):2473–2482

Article  PubMed  CAS  Google Scholar 

Di Maio M, Gallo C, Perrone F (2008) [Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy]. Tumori 94(suppl 2):14–22

PubMed  Google Scholar 

Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH et al (2007) A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 15(9):1023–1033

Article  PubMed  CAS  Google Scholar 

Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24(18):2932–2947

Article  PubMed  CAS  Google Scholar 

Dickersin K, Scherer R, Lefebvre C (1994) Identifying relevant studies for systematic reviews. BMJ 309(6964):1286–1291

PubMed  CAS  Google Scholar 

Clarke M, Oxman AD (ed) (2000) Cochrane Reviewers Handbook 4.1.1 [updated December 2000] In: The Cochrane Library, Issue 4, 2000. Oxford, Update Software

Castro AA, Clark OA, Atallah AN (1999) Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. São Paulo Med J 117(3):138–139

PubMed  CAS  Google Scholar 

Egger M, Smith GD, Altman D (2001) Systematic Reviews in Health Care. BMJ, London

Book  Google Scholar 

Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834

Article  PubMed  CAS  Google Scholar 

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560

Article  PubMed  Google Scholar 

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188

Article  PubMed  CAS  Google Scholar 

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634

PubMed  CAS  Google Scholar 

McQuay HJ, Moore RA (1997) Using numerical results from systematic reviews in clinical practice. Ann Intern Med 126(9):712–720

PubMed  CAS  Google Scholar 

Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354(9193):1896–1900

Article  PubMed  CAS  Google Scholar 

Boccia RV, Gonzalez EF, Pluzanska AG, Clerici G (ed) (2008) Palonosetron (PALO), administered orally or intravenously (IV), plus dexamethasone for preventi. J Clin Oncol 26: (May 20 suppl; abstr 20608)

Brames MJ, Roth BJ, Dreicer R, Bubalo J, Nichols C, Cullen MT et al. (ed) (2006) Palonosetron (PALO) + dexamethasone (DEX) for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) in patients receiving multiple-day cisplatin CT for germ cell cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I Vol 24, No 18S (June 20 Supplement): 8607

Carreca I, Bellomo F, Bronte G, Burgio M, Piazza D, Rizzo S et al. (ed) (2007) Impact of the new 5-HT3 receptor antagonist palonosetron (P) in chemotherapy-induced nausea and vomiting (CINV) control in elderly advanced breast cancer (EABC) patients: comparison with the classic antiemetic agent ondansetron (O). Breast Cancer Symposium

Celio L, Denaro A, Canova S, Gevorgyan A, Bajetta E (2008) Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Tumori 94(4):447–452

PubMed  Google Scholar 

Giralt S, Mangan K, Maziarz R, Bubalo JS, Beveridge R, Hurd DD et al. (ed) (2008) Palonosetron (PALO) for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose melphalan prior to stem cell transplant (SCT). J Clin Oncol 26: (May 20 suppl; abstr 9617)

Grunberg SM, Burgt JAV, Berry S, Rubenstein EB, Berry D (ed) (2004) Prevention of delayed nausea and vomiting (D-CINV): Carryover effect analysis of pooled data from 2 phase III studies of palonosetron (PALO). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) Vol 22, No 14 S (July 15 Supplement): 8051

Hunt TL, Gallagher SC, Cullen MT Jr, Shah AK (2005) Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects. J Clin Pharmacol 45(5):589–596

Article  PubMed  CAS  Google Scholar 

Kadota R, Shen V, Messinger Y (ed) (2007) Safety, pharmacokinetics, and efficacy of palonosetron in pediatric patients: A multicenter, stratified, double-blind, phase 3, randomized study. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I Vol 25, No 18 S (June 20 Supplement): 9570

Labianca R, Mandala M, Clerici M (2008) [Clinical role of palonosetron for patients receiving cisplatin-based chemotherapy]. Tumori 94(suppl 2):23–25

PubMed  Google Scholar 

Pradelli L, Eandi M (2008) [Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in Italy: pharmacologic, clinical and economic aspects]. Tumori 94(suppl 2):26–32

PubMed  Google Scholar 

Rojas C, Stathis M, Alt J, Rubenstein E, Cantoreggi S, Sebastiani S et al. (ed) (2007) Additional binding mechanism of palonosetron to the 5-HT3 receptor versus first generation 5-HT3 receptor antagonists. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I Vol 25, No 18S (June 20 Supplement): 19583

Rubenstein EB, Gralla RJ, Eisenberg P, Sleeboom, Vtoraya O, Macciocchi A et al. (ed) (2003) Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for Prevention of Acute & Delayed Chemotherapy-Induced Nausea and Vomiting (CINV): Combined Results of Two Phase III Trials. Proc Am Soc Clin Oncol 22: (abstr 2932).

Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115–124

Article  PubMed  CAS  Google Scholar 

Sekine I, Saito M, Aogi K, Yoshizawa H, Yanagita Y, Sakai H et al. (ed) (2008) Palonosetron (PALO) versus granisetron (GRAN), both combined with dexamethasone (DEX) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with cisplatin- or anthracycline plus cyclophosphamide-based regimens: Results of a phase III trial in Japanese patients. J Clin Oncol 26: (May 20 suppl; abstr 20749).

Shah AK, Hunt TL, Gallagher SC, Cullen MT Jr (2005) Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr Med Res Opin 21(4):595–601

Article  PubMed  CAS  Google Scholar 

Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9):1441–1449

Article  PubMed  CAS  Google Scholar 

Sepúlveda-Vildósola AC, Betanzos-Cabrera Y, Lastiri GG, Rivera-Marquez H, Villasis-Keever MA, Del Angel VW et al (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 39(6):601–606

Article  PubMed  Google Scholar 

Yu Z, Liu W, Wang L, Liang H, Huang Y, Si X et al (2009) The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer 17(1):99–102

Article  PubMed  Google Scholar 

National Cancer Institute. [October, 2009]; Available from: http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/HealthProfessional/page7

Massa E, Astara G, Madeddu C, Dessi M, Loi C, Lepori S et al (2009) Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. Crit Rev Oncol Hematol 70(1):83–91

Article  PubMed  Google Scholar 

Ellebaek E, Herrstedt J (2008) Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. Curr Opin Support Palliat Care 2(1):28–34

Article  PubMed  Google Scholar 

Aapro MS, Macciocchi A, Gridelli C (2005) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. J Support Oncol 3(5):369–374

PubMed  CAS  Google Scholar 

Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL et al (2005) 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 6(10):765–772

Article  PubMed  CAS  Google Scholar 

Siddiqui MA, Scott LJ (2004) Palonosetron. Drugs 64(10):1125–1132, discussion 33-4

Article  PubMed  CAS  Google Scholar 

Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A (2004) Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 15(2):330–337

Article  PubMed  CAS  Google Scholar 

Grote T, Cartmell A, Phillips N, Yanagihara R (2002) Efficacy of palonosetron (RS-25259) compared with dolasetron in preventing acute and delayed moderately emetogenic chemotherapy-induced nause and vomiting (CNIV): results of a phase III, randomized, controlled trial. Blood 100(11 (Pt 1)):497b

Google Scholar 

Bernardo G, Palumbo R, Frascaroli M, Bernardo A, Losurdo A, Poggi G et al. (ed) (2009) Palonosetron compared to ondansetron in the prevention of chemotherapy-induced nausea and vomiting: Activity, safety, and cost-effectiveness evaluation. J Clin Oncol 27: (suppl; abstr e20573)

Grous JJ, Riegel E, Gabrail N, Charu V, Arevalo-Araujo R, Yanagihara R et al. (ed) (2009) Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV). J Clin Oncol 27:15s, (suppl; abstr 9627)